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2.7%, p= 0.041). In the Capox-RT group, 85.7% (191/223) 
patients received radiotherapy on schedule and 74.9% 
(166/223) with concurrent chemotherapy on schedule, as did 
94.1% (238/253) and 92.1% (233/353) in the Cap-RT group, 
respectively. Grade 3-4 acute toxicity was observed in 38.1% 
of patients in the Capox-RT group and in 29.2% in the Cap-RT 
group (p = 0.041). Grade 3–4 tenesmus was more common in 
the Capox-RT group than in the Cap-RT group (5.4% vs. 2.0%), 
as were grade 3–4 nausea (2.2% vs. 0%), grade 3–4 vomiting 
(1.8% vs. 0%), and grade 3–4 fatigue (3.1% vs. 0.4%). 
Conclusions: The interim analysis revealed that inclusion of 
oxaliplatin into capecitabine based postoperative 
chemoradiotherapy was feasible and could decrease 
cumulative locoregional recurrence rate for patients with 
locally advanced rectal cancer.  
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How can we help patients to make a treatment choice that 
fits them best? (Shared decision making) 
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Traditionally, oncology patients are inclined to follow the 
treatment advice of their physician without asking too many 
questions. However, for many patients different treatment 
options are available. Each option will have its own pros and 
cons, which may be weighed differently by individual 
patients. This calls for shared decision making (SDM) and 
patient involvement in the treatment choice. In order to 
involve patients as partners in decision making, however, 
different steps are required. Patients should be invited to 
participate in the tradeoff between options. They need 
evidence-based information on the risks and benefits of 
different options presented in a structured way, preferably 
using visual aids. And they need to be stimulated to think 
about which aspects are most important to them.  
When available, decision aids are useful tools to give patients 
evidence-based information and to help them make a 
personal tradeoff. Decision aids have proven to be effective, 
e.g. in a recent Cochrane review (2011). Knowledge 
increases, less patients remain undecided on the their 
treatment preference, more patients take an active role in 
decision making, and they are more aware of which 
treatment outcomes are most important to them. As a 
consequence, the treatment choice better fits their personal 
situation and their individual preference.  
Within radiotherapy, we studied patient involvement in the 
choice between a lower or higher radiation dose reflecting 
the tradeoff between the likelihood of cure and the 
likelihood of serious side effects. Other radiotherapy-related 
choices include radiotherapy vs. surgery, radiotherapy vs. 
best supportive care, chemoradiotherapy vs. radiotherapy 
alone or conventional fractionation vs. hyper- or 
hypofractionation.  
Some physicians may hesitate to involve cancer patients in 
treatment decisions. One reason may be that some doctors 
believe they can predict their patients preferences, so they 
don’t need to bother their patients with trade-offs. However, 
preferences for treatment and for involvement appear to be 
hard to predict for physicians, and even for patients 
themselves. Once informed, they become more active 
partners in decision making than they previously predicted, 
and their preferences can differ from what their physicians 
expected. Moreover, sharing information about the pros and 
cons of different treatment options is appreciated by the vast 
majority of patients, even by those who prefer to leave the 
ultimate decision to their physician. 
Other possible barriers for SDM are the assumptions that 
patients are unable to make a consistent choice, that it may 
be a burden for patients to take responsibility for the 
decision or that it may induce regret over the choice later 
on, especially for patients with poor outcome. However, 
research shows that patient choices are consistent with their 
values and concerns. Moreover, anxiety is not increased and 
regret, if anything, appears to be reduced, particularly in 
those patients that experience poor outcome. Finally, the 
idea that shared decision making may be too time consuming 
is not confirmed by the results of recent implementation 
studies. 
Illustrated by our research, (mis)perceptions and tips about 
shared decision making will be discussed. 
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Purpose/Objective: Based on our lab results showing that the 
Farnesyl Transferase Inihibitor, Tipifarnib induced a 
vascularization normalisation, oxygenation and 
radiosensitisation in glioblastoma (GBM) model, we 
performed a phase I-II clinical trial associating Tipifarnib with 
radiotherapy in GBM patients. The aim of this study was to 
assess by dynamic susceptibility contrast MRI (DSC-MRI) the 
effect the combined treatment on tumor perfusion. 
Materials and Methods: Eighteen patients with newly 
diagnosed GBM were included in a phase I-II clinical trial 
associating RT with Tipifarnib, they underwent conventional 
anatomical MR imaging and DSC-MRI before and two months 
after treatment (M0 and M2 respectively). Anatomic volumes 
of interest (VOIs) were defined by contrast-enhanced (CE) 
regions on post-gadolinium based T1 MR images and areas of 
hyper-intense signal on T2 MR images. Perfusion changes 
between M0 and M2 were assessed by measuring the variation 
of the median relative CBV (rCBV) inside these anatomical 
VOIs. Another voxel by voxel analysis of CBV values classified 
138,646 tumor voxels (inside the CE VOI) into High_, Normal_ 
and Low_CBVTUMOR according to the distribution of CBV in the 
contralateral normal tissue: for CBV value higher than the 
95th percentile of the normal contralateral distribution, the 
voxel was classified in the High_CBVTUMOR class (red voxels) ; 
for CBV value between the 25th and the 75th percentile, the 
voxel was classified in the Normal_CBVTUMOR class (green 
voxels) and for CBV value below the 25th percentile, the voxel 
was classified in the Low_CBVTUMOR class (blue voxels). All 
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classes of CBVTUMOR were reported to the total CBVTUMOR to 
show volume variations in percentage. 
Results: Variations of median rCBV between M0 and M2 were 
different for two groups of patients: rCBV increased when 
initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased 
when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was 
statistically significant (p<0.013).  
Mapping of color-coded voxels between M0 and M2 provided 
additional spatial and quantitative information about tumor 
perfusion: Group_rCBV_M0>1 presented a significant decrease 
of High_CBVTUMOR volume (p=0.015) simultaneously with a 
significant increase of the Normal_CBVTUMOR volume (p=0.012) 
after treatment. Group_rCBV_M0<1 presented a significant 
decrease of Low_CBVTUMOR volume (p=0.035) after treatment 
and an increase of the Normal_ and High_CBVTUMOR volumes. 
Two examples of these CBVTUMOR volumes variations between 
M0 and M2 are illustrated for a patient of each group over 
their anatomical MRI, respectively Fig1A for a patient of 
Group_rCBV_M0>1 and Fig1B for a patient of 
Group_rCBV_M0<1.  
 
 
Conclusions: Pre and post-treatment CBV measurements with 
DSC-MRI characterized tumor perfusion evolution in GBM 
patients treated with RT combined to Tipifarnib; showing 
variations in favour of tumor perfusion normalisation in 
agreement with our pre-clinical results of vascular 
normalisation.  
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Purpose/Objective: Lung cancer is the leading cause of 
cancer death worldwide and alternative treatment strategies 
are needed to eradicate non-responsive or recurrent tumor 
cells. The Notch signaling pathway plays a key role during 
normal lung development and is frequently deregulated in 
non small cell lung cancer (NSCLC) making it a potentially 
attractive therapeutic target. We and others have shown that 
in NSCLC xenografts high Notch activity is correlated with 
faster proliferation, higher hypoxic fraction and resistance to 
radiotherapy. These findings have led us to further 
investigate the interactions between standard of care 
treatments (chemo/radiotherapy) in conjunction with Notch 
inhibitors both in vitro and in vivo.  
Materials and Methods: Monolayer cultures of diverse lung 
cell lines were used to determine the IC50 value by 
measuring the metabolic activity of the acid phosphotase 
enzyme in cells after treatment with a range of 
chemotherapeutic agents both as a monotherapy and in 
combination with Notch receptor inhibition. In addition, the 
effect of single and combined treatment schedules was 
tested using a quantitative spheroid growth delay assay. In 
vivo evaluation of therapeutic efficacy of the combination 
treatment before mentioned has been initiated using a 
xenograft lung cancer model.  
Results: IC50 value analysis of various chemotherapeutic 
agents revealed striking differences in responses across cell 
lines. The human lung cancer cell line H460 was more 
sensitive to etoposide, docetaxel and paclitaxel than 
different mouse cell lines deriving from mouse tumors 
bearing KRas and p53 mutations with different metastasizing 
potentialities (344P; 344SQ and 393P) but equally sensitive to 
cisplatin than 344P and 344SQ cell lines. The 393P cell line 
derived from a primary tumor that didn't metastasize was 
more resistant than the rest of the cell lines to cisplatin and 
paclitaxel. Interestingly, although Notch inhibition alone had 
no effect upon cell growth after 72h of treatment, the 
combination with either cisplatin or etoposide resulted in a 
growth delay with respect to the monotherapy treatment. In 
spheroid cultures of H460 cells the combination of 2.5uM 
cisplatin with 4 uM DAPT (Notch inhibitor) instigated more 
growth delay than the monotherapy treatments. Experiments 
to quantify the growth delay when also radiation is given are 
underway. In addition, in vivo experiments are ongoing to 
investigate whether the synergistic drug combination found in 
vitro also applies for an in vivo model. Two different doses of 
cisplatin were tested in vivo whereby 3.5mg/kg had a good 
efficacy and better tolerance than 7mg/kg and therefore will 
be used to test the combination treatment with the dose of 
Notch inhibitor that yields an optimal response as 
monotherapy and with radiation. 
Conclusions: The addition of Notch inhibitors to cisplatin 
(chemotherapeutic used to treat lung cancer patients) leads 
to an enhanced treatment response in vitro and may lead to 
one in vivo as well.  
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Purpose/Objective: Novel targeted agents, such as PARP 
inhibitors, are combined with radiotherapy (RT) to induce 
tumor-specific radiosensitization. Safety and tolerability of 
olaparib in combination with RT is currently tested in several 
clinical phase 1 trials. When used as single agent in clinic, 
olaparib is well tolerated and has proven anti-tumor efficacy 
in BRCA1 and 2 mutation carriers. As the mechanisms of 
action of olaparib as radiosensitizer or as single agent may 
differ, also the dose range of tolerability and effectiveness 
might differ. In this in vitro study, we compared efficacy of 
